Innovative Medicines Initiative – Introduction



what could be more commonplace than going to the doctor's in winter or preparing daily treatments for hospital patients or taking an anti-inflammatory when you're suffering from bone demineralization yet these simple gestures which concern everyone are far from mundane you've got to realize that developing and discovering new drugs is a very complex process it takes us on average 10 to 13 years to bring just one product to the market developing a drug is not only long it's also expensive up to 700 million euros if you actually make it only one drug candidate in 5000 will become a marketable drug the starting point is to seek an assembly of molecules that's active against the target the illness a lot of trials are done and a lot of mistakes are made to find one active assembly of molecules next it has to be proved that the molecular assembly is safe and effective this research is done in vitro on cells and in vivo on animals if the results are positive the drug moves on to the next phase only a very few drug candidates reached this stage research is now carried out on humans on healthy volunteers the test is to see if the drug is toxic or not and whether it's well tolerated in short its safety is tested next tests are done on sick patients during this phase and evaluation is made of whether or not the patient's stage improves the efficacy of the drug is being tested much has been learned about the drug it can therefore be prescribed for a greater number of patients we're talking about hundreds of thousands of patients young people old people people of all origins this is useful to find out if there are any side effects a file is submitted to the health authorities to apply the marketing authorization as soon as this authorizations obtained the drug can be sold nevertheless the drug is permanently monitored after its commercialization the long-term side effects of the treatment its tolerance and the influence of age and sex are studied so it takes between 10 and 13 years to develop a drug for some patients this is too long Kiki is 64 she's been suffering from Alzheimer's disease for five years during which time the condition has deteriorated rapidly today she's taking part in an Alzheimer's cafe a place for discussion and socializing among sufferers here everybody's convinced of the pressing need for curative treatment which a family cannot keep it he don't owe him a unique ability melody exists to be soft on your body treatment karate don't – skipper fair facility la Parisienne development SMED commode well it was a facilitating and speeding up drug development is the philosophy behind the IMI the innovative medicines initiative a private public partnership between the European Commission and the EF BIA the European Association of pharmaceutical industries which brings together more than 1,800 businesses eme aims at improving the drug development process in view of producing better medicines it will not produce new medicines as such its focus will be to do research in to develop new and better methods to predict the safety and efficacy of new drugs the preferred fields are those of cancer cerebral illnesses like Alzheimer's but also inflammatory metabolic and infectious diseases IMI has a total budget of 2 billion euros for the period 2008 to 2013 I am I will bring all stakeholders to the table the in commission industry small companies universities regulatory authorities and patient organizations networking is very important there have been lots of networks established over the last few years and some of them supported by the European Union that's been useful what Amy does I think that is different to the others is it brings real resource to the table the starting point for working in a network is access to knowledge aureus Pharma a small company manages a databank which pulls the results of thousands of previous research projects Latino la Sedona Pokemon today's experiment Asia this Poneke aureus firmer structures the information and makes it electronically accessible for researchers in London researchers at King's College work in partnership on Alzheimer's disease at 80 Arthur is a patient at risk every three months he has a magnetic resonance imaging or MRI scan and a neuropsychological test we measure people's memory and then we use another test which is not much more than the doctor asking the patient and their carer whether they're better or not these are really weak measurements their subjects a lots of fluctuation people have good days and bad days this makes doing a trial difficult if we had a biomarker or a test that accurately measured how somebody was progressing that would speed up the drug development process immeasurably Arthur also has a blood test all the samples are kept in these freezers it's in the blood that scientists are searching for this biological marker the test that will give a first indication of the patient's condition in terms of Alzheimer's and later indicate whether the treatment acts effectively on the patient or not working in networks makes it possible to transfer research results to biopharmaceutical companies that are capable of undertaking applied research also called translational medicine translational medicine is the word that we often use to describe the science being the hopefully integrated science that spans everything that happens in the laboratory and things that happen in the clinic and it's that ability to move from a laboratory test to understanding what might happen in volunteers and patients and human beings that is key to the success of the infinite medicines initiative medicine and shows the smooth transition from the barratry to clinical development and allows drug candidates to be more rapidly and efficiently tested on humans that for example is the aim of the biological market developed in London that's the aim of I am I more safety and more personalized efficacy this is the ultimate goal so that there will be no waste of resources no undue risks for patients but really the response that the right response for the right individual the results collected by IMI will benefit the entire European and world population but what will also improve is European competitiveness vamos amico Darla's competitor european porque trabajando juntos una tarea Kingu no podría assume nila por si solemn new el público el privado Liljegren industria me las páginas empresas ning las universidades podríamos por separado Assuan estos doritos juntos lo podemos hacer yo juntos vamos a conseguir que teníamos la maza Kritika el conocimiento cable era Europa led Roscoe in East Campus in typical

Leave a Reply

(*) Required, Your email will not be published